“Biosimilars” are biologic medicines approved by the FDA as “highly similar” to the original biologic medicine such that they work in the same way and have no clinically meaningful difference in safety or efficacy. Biosimilars increase treatment options in critical disease areas and have the potential to lower health care costs for patients, states (and taxpayers), and insurers. However, the potential of these savings has not yet been realized, and it's important to understand any access barriers that may be contributing factors, and if there are policy solutions that can be explored for greater use and, therefore, savings.